Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
|Videos|July 26, 2017
What is The Benefit of Darunavir Versus Other HIV Medications?
Author(s)Contagion Editorial Staff
Magda Opsomer, MD, explains why darunavir may be more beneficial than other HIV medications.
Advertisement
Magda Opsomer, MD, Director, Clinical Leader, Infectious Diseases and Vaccines, Janssen Pharmaceutical Companies, Belgium, explains why darunavir may be more beneficial than other HIV medications.
Interview Transcript (slightly modified for readability)
“Darunavir is a boosted protease inhibitor and what is special about it is that it has a very high genetic barrier to the development of resistance. [This] is very important when it comes to treating patients, because as we know, resistance makes it more difficult to treat patients at the end.”
Advertisement
Related to this article
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
The guidelines issued by the Department of Health and Human Services (HHS) have been updated with recent, evidence-based consensus of The Panel for the Use of Antiretroviral Agents in Adults and Adolescents.
Labcorp data presented at IDWeek 2026 show measles PCR testing nearly quadrupled and positivity rose sharply from April 2025 through March 2026, as clinicians shift toward guideline-recommended molecular testing amid ongoing US outbreaks.
Advertisement
Advertisement
Trending on Contagion Live
1
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
2
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
3
Cefiderocol Activity Improves in Physiologic Media, Synergizes With LL-37
4
FDA Approves Voceryq, First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis
5